Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Non Operating Investment Income (2018)

Amicus Therapeutics (FOLD) has disclosed Non Operating Investment Income for 1 consecutive years, with -$7.6 million as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Non Operating Investment Income changed N/A year-over-year to -$7.6 million, compared with a TTM value of -$7.6 million through Sep 2019, changed N/A, and an annual FY2018 reading of -$2.7 million, changed N/A over the prior year.
  • Non Operating Investment Income was -$7.6 million for Q2 2018 at Amicus Therapeutics, down from $4.9 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $4.9 million in Q1 2018 and bottomed at -$7.6 million in Q2 2018.